How a Costco partner's bankruptcy could benefit its biggest rival
Synergy CHC Corp., maker of Focus Factor, filed for bankruptcy after Costco ended their 16-year partnership, costing Synergy 58% of its 2025 net revenue. Reckitt Benckiser (RBGLY) is positioned to benefit, as its Neuriva brain supplement is already sold at Costco. RBGLY trades at $14, down 10.62% year-to-date, with H1 2026 revenue growth of 2.7%.
How this was made
The 30-second read
Why it matters
Reckitt's existing Costco relationship positions it to capture displaced demand, but the scale is uncertain.
Market read
The story highlights a potential shift in market share within the consumer health supplement space, primarily affecting Reckitt Benckiser.
What to watch
Potential supply chain constraints and consumer price sensitivity could temper demand.
Background
Synergy CHC's Chapter 11 filing removed a major Costco supplier, creating an opening for competitors.
Ticker impact
Reckitt Benckiser (RBGLY) could gain market share after Synergy CHC's bankruptcy ends its Costco partnership.
Modest upside as investors price in higher sales to Costco.
The article outlines a clear beneficiary relationship, but no concrete sales numbers are provided.
Market effects
Consumer health supplement sector may see a shift in Costco shelf space toward larger, regulated brands.
U.S. retail supplement market could see modest reallocation of sales.
Limited to markets where Costco operates and Reckitt has presence.
Counterpoint
Reckitt may face integration challenges and competition from other supplement brands, limiting upside.
Key entities
- companySynergy CHC Corp.
Focus Factor manufacturer that filed for Chapter 11.
- retailerCostco
Major retailer that discontinued Focus Factor, triggering the bankruptcy.
